Natalie Sainz, in diaTribe Learn, reports that a new international consensus of recommendations for the standard use of continuous glucose monitoring (CGM) data in clinical trials has been published in the January issue of The Lancet Diabetes & Endocrinology.
The diaTribe Foundation, Advanced Technologies & Treatments for Diabetes (ATTD), and the Time in Range Coalition led a seven-month effort to achieve international agreement. In April 2022, the three organizations gathered 33 of the world’s top diabetes experts in Barcelona, Spain, to discuss these recommendations, with the consensus achieved being hailed as an essential step toward increasing the use of CGM metrics, including time in range, in clinical trials to advance potential breakthroughs in diabetes care.
In total, 23 recommendations are included in the publication, which also cover the specific glucose metrics researchers should evaluate and report, information on clinically relevant changes in key glucose metrics over time, and training for both trial staff and participants.
To read more, CLICK HERE.
